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In the present work, sixty substituted 2-Phenylimidazopyridines previously reported with potent anti-
human African trypanosomiasis (HAT) activity were selected to build genetic algorithm (GA) based
QSAR models to determine the structural features that have significant correlation with the activity.
Multiple QSAR models were built using easily interpretable descriptors that are directly associated with
the presence or the absence of a structural scaffold, or a specific atom. All the QSAR models have been
thoroughly validated according to the OECD principles. All the QSAR models are statistically very robust
(R2 ¼ 0.80e0.87) with high external predictive ability (CCCex ¼ 0.81e0.92). The QSAR analysis reveals
that the HAT activity has good correlation with the presence of five membered rings in the molecule.
© 2016 Elsevier B.V. All rights reserved.1. Introduction
Sleeping sickness or human African trypanosomiasis (HAT),
transmitted by tsetse flies (genus Glossina), has a major occurrence
in rural populations in sub-Saharan Africa. HAT, considered as a
neglected tropical disease, was nearly eradicated in the mid-1960s.
The resurgence in the late 1990s, due to poor sanitation and suit-
able habitats for its vector in the Democratic Republic of the Congo
(DRC), Angola, Central African Republic, southern Sudan, and
Uganda, received considerable attention of the researchers to
develop better diagnosis and treatment for the disease [1e3].
Recent reports indicate that in humans the disease is thought to be
mainly caused by Trypanosoma brucei gambiense and Trypanosoma
brucei rhodesiense, however the non-human-pathogenicasis; GA, Genetic algorithm;
e structure-activity analysis;
n, Distribution, Metabolism,
ARINS-Chem, QSAR Insubria-
ation and Development.
sand).trypanosome species Trypanosoma brucei brucei, Trypanosoma
congolense, and Trypanosoma evansi are also responsible in some
instances [1]. The disease has two stages; in stage 1 (hemolym-
phatic) the peripheral infection with non-specific clinical symp-
toms occur; and in stage 2 the parasite crosses the blood brain
barrier (BBB) and intrudes the central nervous system (CNS) [1e3].
Suramin and pentamidine are the recommended drugs for stage
1 infection, whereas for stage 2, the therapeutic options are mel-
arsoprol, eflornithine and the currently used combination therapy
NECT (nifurtimox and eflornithine combination therapy). Unfor-
tunately, vaccine cannot be developed due to a high degree of
antigenic variation. In addition, the treatment is parasite- and
stage-specific, depending on the ability of the compound to cross
the BBB. For BBB clearance the drug must be sufficiently lipophilic,
which results in poor water solubility, hence, such drugs are mostly
toxic and problematical to administer. Consequently, the available
drugs for stage 2 of the disease exhibit high toxicity, involve the
complexity of administration procedures and progressive loss of
efficacy in some geographical regions. Recent efforts identified
Fexinidazole, furamidine, DB289 (parafuramidine), CPD-0802 (an
aza analogue of parafuramidine) and SCYX-7158 (a boron based
compound) as attractive lead/targets in the drug pipeline for
V.H. Masand et al. / Journal of Molecular Structure 1130 (2017) 711e718712developing better therapeutics for HAT (see Fig. 1). Despite the
previous efforts executed high toxicity, poor oral bioavailability and
bloodebrain barrier penetration are the major obstacles ahead for
these clinical candidates. Thence, the search for a drug candidate
with adequate activity, ADME and toxicity profile still persists
[1e4].
Recently, Tatipaka et al. [5] identified substituted oxazolopyr-
idine 1 (see Fig. 2) as an attractive lead due to good whole-cell
activity on T. brucei, no cytotoxicity on mammalian cell lines,
acceptable exposure in the central nervous system, and satisfactory
aqueous solubility. But, its poor metabolic stability in liver micro-
somes appeared as a severe liability. Later, to design a better
analogue of 1 with the desired profile, they synthesized and
screened a series of substituted 2-Phenylimidazopyridines. Since,
the mechanism of action and the specific target with which these
analogues interact is unknown [5]; in such a situation, a good
strategy for lead optimization is to employ computer aided drug
design (CADD) using the available information. Hence, in the pre-
sent work, ligand based drug design technique, viz. QSAR (2D- and
3D-) has been executed to determine the structural features having
a significant correlation with the HAT activity profile of substituted
2-Phenylimidazopyridines.
In the past decades, CADD has appeared as a thriving option to
conventional ‘trial and error’ methodology of drug design/discov-
ery to unknot the mysteries of structural patterns that govern the
activity, pharmacokinetics, pharmacodynamics and toxicity pro-
files of a drug candidate. CADD is relatively fast, economical and
significantly result oriented successful in-silico technique [6e10]. It
encompasses a combination of different ideas, algorithms, tools
and techniques of various scientific fields like computer, mathe-
matics, statistics, etc. Its major emphasis is on simulation of in-
teractions of different molecules, to determine the reasons behind
the specific interactions of different molecules and identification of
effective structural features associated with activity/toxicity. QSAR,
molecular docking, pharmacophore modeling, etc. are established
CADD methods, which when used in harmony provide significant
and unrivalled information essential for lead/drug optimization
[4,11e15]. These methods have been widely used for identification
of the structural patterns that govern the specific activity/toxicity of
drug candidates and provide better insight into the mechanism of
drug action.
Themain objective of the present work is to develop statistically
robust and easily interpretable, in terms of structural fragments orFig. 1. Chemical structures of clinicaspecific atom, QSAR models with high external predictive ability.2. Experimental methodology
2.1. Experimental datasets
In the present work, HAT inhibition activities of sixty substituted
2-Phenylimidazopyridines comprising different heterocyclic scaf-
folds and diverse substituents at various positions covering a
meaningful portion of the chemical space were subjected to QSAR
modeling [5]. The reported EC50 (mM) values for HAT activity were
converted to pEC50 (-log10EC50) before QSAR analysis. The EC50,
pEC50 and the substituents on 2-Phenylimidazopyridine moiety
have been listed in Table 1.2.2. Modeling and molecular descriptors calculation
In the present work, a QSAR analysis following the standard
procedure recommended by OECD and different researchers was
exercised [16e26]. The chemical structures were drawn using
ChemSketch 12 freeware followed by energy minimization using
MMFF94 force field in TINKER [4,12,15]. The optimized structures
were used as input for the calculation of a good number of 1-3D,
electro-topological, fingerprints and other descriptors. Two
descriptor calculating softwares were used: PaDEL 2.21 and e-
Dragon. Since, all the calculated descriptors (>18,000) do not contain
significant information; objective feature selection was employed to
reduce the descriptor pool. Nearly constant (>95%), constant, and
highly correlated (jRj > 95%) descriptors were eliminated before
subjective feature selection (SFS) using QSARINS-Chem 2.2.1
[16,17,20]. This resulted in a reduced cluster of 345 descriptors only.
The very next step involved the elimination of highly esoteric de-
scriptors, the descriptors for which an exact explanation is not
available or it is difficult to interpret it in terms of structural features
[26]. This led to a set of only 253 easily interpretable descriptors. The
reduced set still consists a wide range of theoretical molecular de-
scriptors that takes into account different structural features, viz.
constitutional (0D-), mono-dimensional (1D-), bi-dimensional (2D-)
and three-dimensional (3D-), capturing and magnifying the diverse
aspects of the chemical structures.l drug candidates against HAT.
Fig. 2. Chemical structure and profile of substituted oxazolopyridine 1.
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2.3.1. QSAR model
The very first principles and applications of QSAR analysis are to
gain maximal information of activity related structural features and
to predict the desired activity of a molecule before its actual syn-
thesis and bio-screening. Hence, in order to achieve these goals
easily interpretable descriptors were considered during model
generation and multiple QSAR models were developed using
divided and undivided datasets [19,27,28]. The dataset was divided
into a training (80%) and a prediction (or test) (20%) sets in random
fashion before descriptor selection. Multiple splitting were
employed to develop multiple QSAR models [12,15], in this way a
molecule in the training set of a splitting may or may not be in the
training set of another splitting. Therefore, the multiple QSAR
modeling approach ensured that maximum number and informa-
tion is gained for molecular descriptors that govern the biological
profile of the molecules. GA (Genetic Algorithm) module of
QSARINS-Chem 2.2.1 was utilized for the selection of optimum
number and set of descriptors. For the sake of simplicity and to
avoid the problem of over-fitting, the heuristic search of descriptors
was limited to four descriptors using the default settings in
QSARINS-Chem 2.2.1. Q2loo was used as a fitness function to avoid
the problem of naïve Q2. The strategy used in QSAR model devel-
opment has been summarized in Fig. 3 [12,15,24].
For development of QSAR models 6e10, HeuristicLab 3 was
employed using different operand using the default settings.
2.4. Model validation
All QSAR models need to be appropriately validated to ascertain
its predictive ability and utility. The statistical qualities and validity
of the QSAR models were established by means of: (a) internal
validation or cross-validation (CV) by leave-one-out (LOO) and
leave-many-out (LMO) procedure; (b) using the prediction set; (c)
data randomization i.e. Y-scrambling and (d) examining if the
following conditions are satisfied [12,15]: R2tr  0.6, Q2loo  0.5,
Q2LMO  0.6, R2 > Q2, R2ex  0.6, RMSEtr < RMSEcv, DK  0.05,
CCC  0.80, Q2Fn  0.60, r2m  0.6, (1r2/ro2) < 0.1, 0.9  k  1.1 or
(1r2/r'o2) < 0.1, 0.9 k’ 1.1, jro2r'o2j< 0.3with RMSE andMAE close
to zero. The threshold values of these parameters confirm the
robustness and good external predictive ability of a GA-MLRmodel.
Thus, all the models having low internal and external predictive
ability were subsequently rejected.
3. Results and discussion
3.1. QSAR models
The GA analysis resulted in the generation of a good number of
MLR models with nearly similar statistical performance but
encompassing different descriptors. In such a situation, the usual
practice followed by a QSAR modeller is to select only one MLR
model on the basis of its statistical performance. However, this ‘firstamong equals’ approach is with following drawbacks [12,15] (1) a
QSAR model consisting of only esoteric descriptors, suitable and
realistic description in terms of structural features is highly prob-
lematic and challenging, (2) The single QSAR model may not be
based on (i) appropriate composition of training and test sets, (ii)
sufficient chemical and biologic space i.e. appropriate applicability
domain, (3) the single QSAR model might have high predictive on a
particular prediction set, but poor predictivity on another predic-
tion set. To overcome these drawbacks of ‘first among equals’
approach, building and reporting multiple models or consensus
modeling are two easy, practicable and efficient solutions. Recently,
it has been established that developing multiple QSAR models
based on divided and undivided dataset enhance the efficacy of
QSAR in determining the dominant and concealed structural fea-
tures that have significant correlation with the activity [12,15].
Therefore, in the present study, multiple QSAR models have been
built following the OECD principles for acceptable QSAR models.
This approach led to generation of ten QSAR models possessing
excellent statistical performance. The GA-MLR QSAR models along
with different statistical parameters, tabulated in Table 2, are as
following:3.2. Model-1 (Undivided dataset)
pEC50 ¼ 6.486 (±0.378)  0.214 (±0.067) * C-024 þ 0.756
(±0.273) * nR05e1.087 (±0.318) *F09[NeF] þ 0.897 ((±0.169) *F10
[CeF].3.3. Model-2 (Undivided dataset)
pEC50 ¼ 4.218 (±0.514) þ 0.449 (±0.141) *F02[NeN] þ 0.842
(±0.265) * nR05e0.570 (±0.305) *F09[NeF] þ 0.453 (±0.147) *F10
[CeF].3.4. Model-3 (Divided dataset)
pEC50 ¼ 5.148 (±0.537) þ 0.518 (±0.399) *B10[CeF] þ 0.624
(±0.292) * nR05e0.558 (±0.476) *B09[NeF] þ 1.178 (±0.404) *B07
[NeF].3.5. Model-4 (Divided dataset)
pEC50 ¼ 5.729 (±0.258)e1.328 (±0.724) * nArNR2 þ 1.450
(±0.337) * nPyrrolidinese0.507 (±0.254) *F10[NeF] þ 0.308
(±0.100) *F09[CeF].3.6. Model-5 (Divided dataset)
pEC50 ¼ 5.789 (±0.258)e1.375 (±0.743) * nArNR2 þ 1.322
(±0.331) * nPyrrolidinese0.015 (±0.008) *G(N..F) þ 0.381 (±0.121)
*F09[CeF].
Table 1
Different substituted 2-Phenylimidazopyridines along with reported IC50 and pIC50.
S.No. R1 R2 EC50 (mm) pEC50(M)
1. H Cl 0.22 6.658
2. H F 0.12 6.921
3. H Me 0.43 6.367
4. H CN 0.4 6.398
5. Br F 0.23 6.638
6. CN F 0.38 6.42
7. phenyl F 0.04 7.398
8. 4-fluorophenyl F 0.05 7.301
9. 3-chlorophenyl F 0.05 7.301
10. 4-MeO-phenyl F 0.17 6.77
11. 4-phenylphenyl F 0.42 6.377
R1 R2 R3 EC50 (mM) pEC50(M)
12. 5-methylfuran-2-carbonyl H F 0.2 6.699
13. 3-methylfuran-2-carbonyl H F 0.1 7
14. 3-furanoyl H F 0.15 6.824
15. benzoyl H Cl 7.1 5.149
16. oxazole-5-carbonyl- H F 1.9 5.721
17. 2-thiophenoyl H Cl 1.5 5.824
18. 3-pyridinecarbonyl- H F 7 5.155
19. pyrazine-2-carbonyl- H F 0.9 6.046
20. N-methylpyrrole-2-carbonyl- H F 1.1 5.959
21. methylsulfonyl H Cl 6.1 5.215
22. 2-furancarbothioyl- H F 0.41 6.387
23. 2-furanoyl 2-acetyl F 0.5 6.301
24. 2-furanoyl 2-furanoyl F 0.12 6.921
25. benzyl benzyl F 1.1 5.959
26. methylcarbamoyl H F 3.8 5.42
27. isopropylcarbamoyl- H Cl 1 6
28. phenylcarbamoyl- H Cl 12 4.921
29. dimethylcarbamoyl- H Cl 0.4 6.398
30. 1-pyrrolidinoyl- H Cl 0.09 7.046
31. 1-piperidinoyl- H Cl 1.9 5.721
R1 R2 EC50 (mM) pEC50(M)
32. 2-furanyl H 0.2 6.699
33. 2-furanyl Cl 0.07 7.155
34. 2-furanyl F 0.2 6.699
35. 2-furanyl 5-Cl 10 5
36. 2-furanyl 7-Cl 0.12 6.921
37. N-pyrrolidinyl Cl 0.05 7.301
38. N-pyrrolidinyl phenyl 0.002 8.699
39. N-pyrrolidinyl 3-methoxyphenyl 0.01 8
40. N-pyrrolidinyl 2-methoxyphenyl 0.005 8.301
41. N-pyrrolidinyl 3-Cl-phenyl 0.002 8.699
42. N-pyrrolidinyl 2-chlorophenyl 0.005 8.301
43. N-pyrrolidinyl 3-acetylphenyl 0.003 8.523
44. N-pyrrolidinyl 3-Me-phenyl 0.002 8.699
45. N-pyrrolidinyl 3-trifluoromethoxyphenyl 0.03 7.523
46. N-pyrrolidinyl 3-methyl-4-fluorophenyl 0.02 7.699
47. N-pyrrolidinyl 3-NH2-phenyl 0.01 8
48. N-pyrrolidinyl 3-furanyl 0.004 8.398
49. N-pyrrolidinyl 3-thiophenyl 0.002 8.699
50. N-pyrrolidinyl 2-thiophenyl 0.004 8.398
51. N-pyrrolidinyl 3-pyridyl 0.005 8.301
Table 1 (continued )
R1 R2 EC50 (mM) pEC50(M)
52. N-pyrrolidinyl 5-(2-chloropyridyl) 0.01 8
53. N-pyrrolidinyl 4-(2-chloropyridyl) 0.004 8.398
54. N-pyrrolidinyl 5-(3-methylpyridyl) 0.01 8
55. N-pyrrolidinyl 5-(2-methoxypyridyl) 0.005 8.301
56. N-pyrrolidinyl 5-(3-pyrrolidino) 0.02 7.699
57. N-pyrrolidinyl 5-(3-chloropyrimidinyl) 0.005 8.301
58. N-pyrrolidinyl 5-pyrimidinyl 0.03 7.523
59. N-pyrrolidinyl 5-(2-methoxypyrimidinyl) 0.06 7.222
60. N-pyrrolidinyl 5-(2-chloropyrimidinyl) 0.04 7.398
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pEC50 ¼ 8.455 (±0.292)e0.013 (±0.006) *G(N..F)e1.410 (±0.392)
* invsqr-nR05e1.440 (±0.273) *B03[NeO] þ 0.318 (±0.134) *F10
[CeF].
3.8. Model-7 (Undivided dataset)
pEC50 ¼ 9.122 (±0.407)e0.013 (±0.006) *G(N..F)e1.217 (±0.341)
* invsqr-nR05e0.846 (±0.159) * expB03[NeO]þ 0.317 (±0.135) *F10
[CeF].
3.9. Model-8 (Divided dataset)
pEC50 ¼ 8.162 (±1.455)e0.022 (±0.021) * Sse2.053 (±0.442) *
invcube-nR05 þ 0.948 (±0.263) * C-041 þ 0.901 (±0.325) *B10
[CeF].
3.10. Model-9 (Divided dataset)
pEC50 ¼ 8.540 (±0.458)e0.015 (±0.011) *G(N..F)e1.603 (±0.450)
* invsqr-nR05e1.416 (±0.355) *B03[NeO] þ 0.340 (±0.160) *F10
[CeF].
3.11. Model-10 (Divided dataset)
pEC50 ¼ 7.675 (±0.331) þ 0.388 (±0.308) * Cl-089e1.485
(±0.412) * invcube-nR05e1.118 (±0.316) *B03[NeO] þ 0.672
(±0.308) *B10[CeF].
The statistical symbols have their usual meaning [12,16,17,20,23]
and are available in the supplementary material, also. From sta-
tistical analysis (Table 2), it is clear that all the developed QSAR
models are statistically robust and possess good external predictive
ability, especially, the models 6e10. The models 6e10 outperform
their counterparts apropos of fitting, internal validation and
external predictivity criteria. As expected, establishing the models
6e10 helped in the identification of less dominant descriptors like
Ss (sum of Kier-Hall electrotopological indices), G(N..F) (sum of
geometrical distances between N and F), C-041 (an atom-centered
fragment representing XC(¼X)X), and Cl-089 (an atom-centered
fragment representing Cl attached to sp2 hybridized C) with cor-
relation with the activity, which were not discovered while build-
ing the models 1e5. For all the developed models, the value of R2adj.
is quite close to R2tr suggesting that the number of descriptors in
the models are not too high, thereby, indicating that the models are
free from over-fitting [26]. This is further supported by the low
value of LOF (Lack of fit) for all the models. The low Kxx
Fig. 3. Strategy used for developing the QSAR models.
Table 2
Statistical performance of different QSAR models.
S.No. Statistical Parameter Model-1 Model-2 Model-3 Model-4 Model-5 Model-6 Model-7 Model-8 Model-9 Model-10
1. Ntr 60 60 48 48 48 60 60 48 48 48
2. Nex e e 12 12 12 e e 12 12 12
3. Number of Descriptors 4 4 4 4 4 4 4 4 4 4
Fitting Criteria
4. R2tr 0.807 0.806 0.822 0.823 0.812 0.863 0.862 0.839 0.876 0.874
5. R2adj. 0.793 0.792 0.806 0.806 0.794 0.853 0.852 0.824 0.865 0.863
6. R2tr - R2adj. 0.014 0.014 0.016 0.017 0.018 0.010 0.010 0.015 0.012 0.012
7. LOF 0.288 0.289 0.292 0.301 0.312 0.205 0.206 0.246 0.214 0.217
8. Kxx 0.255 0.300 0.398 0.365 0.406 0.441 0.440 0.306 0.478 0.374
9. DK 0.119 0.139 0.119 0.064 0.058 0.064 0.063 0.131 0.080 0.104
10. RMSEtr 0.465 0.466 0.450 0.457 0.466 0.392 0.394 0.413 0.385 0.389
11. MAEtr 0.354 0.358 0.349 0.362 0.383 0.312 0.313 0.320 0.307 0.314
12. RSStr 12.981 13.028 9.733 10.034 10.414 9.232 9.302 8.190 7.119 7.248
13. CCCtr 0.893 0.893 0.903 0.903 0.896 0.926 0.926 0.913 0.934 0.933
14. s 0.486 0.487 0.476 0.483 0.492 0.410 0.411 0.436 0.407 0.411
15. F 57.446 57.191 49.749 49.841 46.345 86.363 85.610 56.177 76.220 74.679
Internal Validation Criteria
16. R2cv (Q2loo) 0.776 0.770 0.784 0.777 0.753 0.840 0.839 0.800 0.847 0.844
17. R2-R2cv 0.031 0.036 0.038 0.046 0.059 0.022 0.023 0.039 0.029 0.030
18. RMSEcv 0.501 0.508 0.496 0.513 0.533 0.423 0.425 0.461 0.428 0.432
19. MAEcv 0.382 0.394 0.389 0.411 0.442 0.340 0.341 0.358 0.344 0.351
20. PRESScv 15.041 15.472 11.824 12.629 13.650 10.740 10.837 10.190 8.809 8.974
21. CCCcv 0.877 0.874 0.882 0.881 0.867 0.914 0.914 0.892 0.919 0.917
22. Q2LMO e e 0.774 0.792 0.771 0.830 0.827 0.787 0.842 0.841
23. R2Yscr e e 0.081 0.086 0.087 0.069 0.069 0.086 0.087 0.082
24. Q2Yscr e e 0.151 0.178 0.231 0.137 0.137 0.144 0.144 0.144
External Validation Criteria
25. q* e e 10.983 3.116 2.325 e e 2.183 2.328 1.261
26. RMSEex e e 0.570 0.479 0.417 e e 0.512 0.441 0.483
27. MAEex e e 0.421 0.351 0.310 e e 0.442 0.350 0.402
28. PRESSext e e 3.894 2.756 2.085 e e 3.148 2.330 2.801
29. R2ex e e 0.673 0.838 0.924 e e 0.819 0.779 0.787
30. Q2-F1 e e 0.690 0.748 0.830 e e 0.807 0.759 0.711
31. Q2-F2 e e 0.673 0.713 0.800 e e 0.804 0.752 0.702
32. Q2-F3 e e 0.716 0.805 0.849 e e 0.753 0.838 0.806
33. CCCex e e 0.805 0.886 0.916 e e 0.905 0.882 0.875
34. r2m aver. e e 0.541 0.654 0.776 e e 0.741 0.687 0.657
35. r2m delta e e 0.257 0.180 0.094 e e 0.040 0.069 0.197
36. R2-ExPy e e 0.785 0.780 0.756 e e 0.801 0.848 0.845
37. R'o2 e e 0.740 0.747 0.712 e e 0.765 0.829 0.823
38. k' e e 0.996 0.997 0.993 e e 0.996 0.998 0.997
39. 1-(R2/R'o2) e e 0.057 0.042 0.059 e e 0.044 0.022 0.025
40. r'2m e e 0.413 0.639 0.597 e e 0.650 0.731 0.722
41. Ro2 e e 0.784 0.777 0.753 e e 0.800 0.847 0.844
42. k e e 0.999 0.998 1.002 e e 0.999 0.999 0.999
43. 1-(R2-ExPy/Ro2) e e 0.001 0.004 0.004 e e 0.001 0.001 0.001
44. r2m e e 0.767 0.737 0.716 e e 0.780 0.829 0.829
R2 e correlation coefficient, Q2 e leave-one-out ‘cross validated R2’, R2adj - adjusted R2, SEE e standard error of estimates, RMSE - root mean squared error, MAE - mean
absolute error, CCC - concordance correlation coefficient, for the training (tr), and test (ex) sets; LOF - lack of fit, F e Fischer's value; R2LMO and Q2LMO e leave many-out
correlation coefficient and cross-validation coefficients; R2Ycr and Q2Ycr e Ye- scramble correlation and cross-validation coefficients.
V.H. Masand et al. / Journal of Molecular Structure 1130 (2017) 711e718 715(representing inter-correlation among descriptors) value in all the
models indicates that low correlation among the descriptors used
in a model [16,17,20]. The condition RMSEtr < RMSEcv is satisfied by
all the developed models. The values of cross validation parametersQ2, Q2LMO and CCCCV for the developed models are high, thereby,
indicating the statistical robustness of the models. The low value of
R2Yscr and Q2Yscr for all the models indicates that the models have
not been developed by chance. For the models 3e5 and 8e10, the
Fig. 4. Exemplification of F02[NeN] descriptor and H-bond donor/acceptor pattern associated with F02[NeN] using molecule 38 as a representative.
Fig. 5. Different possible tautomeric forms of 38.
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Q2-F3, CCCex, etc. indicate the models possess high external pre-
dictivity. This is further supported by the low value of RMSEex,
MAEex, and PRESSext. In short, the developed models satisfy the
recommended interrelations and threshold values for various sta-
tistical parameters suggested by different researchers. Interest-
ingly, for model 5 a very rare observation is identified, the value of
Q2-F1 (¼ 0.830) is greater than R2 (¼ 0.812), thus, the model is able
to predict new data better than fitting available ones, indicating
that the molecules for which this model fits better are present in
the prediction set [15,29,30]. This is again supported by the higher
value of R2ex than R2.
A commonly encountered problem associated with QSAR anal-
ysis is the interpretation or correlation of descriptors with specific
structural fragment or atom. Therefore, in the present work, easily
interpretable descriptors that are directly associated with the
presence or the absence of a structural scaffold, or a specific atom
were considered. This could be highly beneficial to synthetic
chemists for future synthetic strategies.
In models 1e3, the 2D-constitutional type of descriptor ‘nR05’,
representing the presence of a five membered ring, is present with
a positive coefficient. The descriptors ‘invsqr-nR05’ and ‘invcube-
nR05’ represent the inverse of square or cube of ‘nR05’, respec-
tively, and have negative coefficients in models 6e10. Therefore, itappears that the presence of five membered rings in the molecules
increases the activity. This observation is vindicated by comparing
the activity of 1 with 15, and 2 with 18, as representatives. There-
fore, in future modifications five membered ring must be retained
to increase the activity. The 2D-descriptors, F09[NeF] and B09
[NeF], which correspond to the frequency and presence/absence of
N and F at a topological distance of 9, respectively, have a negative
correlation with the activity. Interestingly, in models 1e3, the
positive correlation of F10[CeF] and B10[CeF], which correspond to
frequency and presence/absence of C and F at a topological distance
of 10, respectively, with HATactivity indicates that the presence of F
favors the activity. This is again supported by the positive correla-
tion of B07[NeF], which represents the presence/absence of N and F
at topological distance of 7, in model 3.
The descriptor C-024, an atom centered descriptor corresponds
to ReCHeR fragment, has a negative coefficient in model-1, hence,
its value must be kept as low as possible. The descriptor ‘nPyrro-
lidines’ indicates the presence of number of pyrrolidine rings in the
molecule, its presence is beneficial for activity, as evident from its
positive coefficient in model 4 and 5. The descriptor ‘nArNR2’
which stands for the presence of number of tertiary amines (aro-
matic) in the molecule has a negative association with the activity,
hence such groups must be avoided in future modifications. F02
[NeN] is a finger print descriptor that represents the frequency of
V.H. Masand et al. / Journal of Molecular Structure 1130 (2017) 711e718 717the presence of two nitrogen atoms at a topological distance of 2, its
positive coefficient in the model 2 points out its positive influence
on the activity. This descriptor has been depicted by red bonds in
Fig. 4 using the molecule 38 as a representative. This descriptor is
associated with an interesting pharmacophoric pattern of H-bond
donor and acceptor nitrogen atoms present in a specific arrange-
ment, inwhich a H-bond donor (like N2) is at a topological distance
of 2 from at least one H-bond acceptor N (like N1 or N3).
The importance of this structural pattern is further supported by
the fact that the presence of 5-chloropyridin-2-yl, as in N-(3-((5-
chloropyridin-2-yl)carbamoyl)-4-fluorophenyl)furan-2-
carboxamide, has negative influence on the activity. The compound
N-(3-((5-chloropyridin-2-yl)carbamoyl)-4-fluorophenyl)furan-2-
carboxamide (EC50 ¼ 7 mM) was not incorporated during the QSAR
and pharmacophore model building, as the aim of the present work
was to analyze the bicyclic derivatives only.
This interesting pattern of H-bond donor/acceptor nitrogen
atoms also helps in attaining various tautomeric forms, thereby,
providing additional flexibility to the molecules to acquire bio-
active tautomeric form(s) while interacting with the target recep-
tor. It has been established that a less stable tautomeric form of a
molecule could be the true bioactive tautomeric form [12]. Thus,
tautomeric transformations could be a possible reason behind
higher activity of the molecules bearing imidazopyridine ring. Such
a useful flexibility is diminished when an oxazolopyridine ring is
present instead of an imidazopyridine ring. The various tautomeric
forms along with their calculated distribution (using the software
MarvinSketch 5.0) for the molecule 38, as a representative, have
been depicted in Fig. 5.
The descriptor B03[NeO], which represents the presence/
absence of N and O at a topological distance of 3, or its exponential
expB03[NeO] have negative coefficients in the model 6,7, 9, and 10.
Therefore, the presence/absence of N and O at a topological dis-
tance of 3 has negative influence on the activity. Hence, such a
combination of N and O must be avoided for better activity profile.
This is supported by the observation that in the present series the
molecules bearing oxazolopyridine ring, in general, are less active
than those having an imidazopyridine ring.4. Conclusions
The QSAR analysis revealed important information and obser-
vations about the structural features that steer the HAT activity of
substituted 2-Phenylimidazopyridines. The developed models are
statistically robust with high external predictive ability. The
development of multiple QSAR models helped in identifying less
dominant, but very useful descriptors, which have significant cor-
relation with the activity. The QSAR models pointed out that the
presence of five membered rings, especially the pyrrolidine ring, is
beneficial for the HAT activity of the present series molecules.Acknowledgements
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